I like others hate to defend AF because I have been on the opposite side of his recommendations more often than not, but here's a short story. Some of you may recall a heavily shorted stock named Genta. AF and longs had a very heated debate. AF personally called me to warn me about GNTA. I politely agreed to disagree. He was right, I lost a lot of money, a trading job and some close friends to whom I had recommended the stock lost money. I frequently disagree with AF, but I do have some respect for him as a person. He has relationships with hedge funds that do a lot more homework than most retail longs have the time, resources, or expertise to do. So far, most vaccines either have not worked, or in the case of Provenge, have not been commercially successful. I invest in biotech exclusively, I know it's a big risk, my only advice is to not risk more than you can afford to lose. Good luck.
I certainly understand people investing and losing and being angry. I agree he is a tool, opinionated, lacking scientific rigor, a mouth piece for shorts talking their book, but it's foolish and wrong to threaten him on a MB for many reasons. Maybe the shorts are writing this to try and tick him off; longs would be best to ignore him since he has apparently turned positive on ARNA.
I think it would be very risky to buy before they report data. IMO of course, something smells.
so what, everyone knows Adam is not an analyst, not an MD. He has been following biotech for several years, he has learned a few things, he's frequently wrong and sometimes right and he gets most of his information from hedge fund sources talking their own book. Case closed. Gale investors are in a bad situation and should probably fell the scene.
In the case of IMGN 25 years of nothing so far. Many shareholders who feel positive about the science are waiting for a breakthrough, change in management, or sale to a company with management that can develop drugs. Many larger biotech's and pharma firms want to increase their oncology pipeline and technology, IMGN can do fit the need if management and the BOD were willing and able. They seem to be satisfied with the status quo, earning their paychecks, free options and ignoring the shareholder/owners. We need a large institution to get active, or a new owner that is looking to shake things up. Some day...
they are both a plus and since the ads have not yet started, AF might be the first tipping point, but ads will be much bigger. Anyway, I gave you a thumb's up JDS, happy Valentine's Day.
maybe a couple of weeks, weather is still terrible in the Northeast and Southeast. Love to see that 7 handle!
Longs want more, investors who are out want in and shorts need to cover. Sounds like supply and demand are in favor of ARNA longs as long as management does not create more supply.
Not sure about your high price dreams, only because there are so many shares outstanding, but if Bel sales grow, Bel Phen is successful, Bel works for other indications and the pipeline matures and something els looks like a winner, anything is possible. Let's see if ARNA can break $8 first before we consider even double digits.
Anyone following, or investing in SNTA? They had some insider buying and Jeffries is recommending them. I have never analyzed, or owned the stock, so interested in any educated opinions. Thanks.
Looks more like the next AVEO or DSCO to me. Sorry for perpetuating this Off Topic post, but people should beware of pumpers spreading info on junk stocks.
Good to know Audet is presenting again, they should keep the other employees in the office and away from the mike.
this is a good idea! I know some of the analysts like Thomas Wei at Jeffreys are bullish on ARNA due to the potential for Bel-Phen, so I hope they are not backing away from that. So far, Bell alone is not setting the world on fire, or selling like hot cakes.
This is a very small study 15 patients, insignificant.
not the patients. Obese people are already at an increase for heart risks. Losing weight will be a plus for patients and their heart health. If they have side effects, or the products doesn't work for them, they can stop taking it with very little risk. Please review clinical trial data shorts.
Must be, this stock just wants to go up no matter what the results. I looked at the PR and thought the stock would be down. I guess SGEN shareholders are just smarter, than us dumb IMGN shareholders. I am hoping SGEN will drag our sorry #$%$ IMGN stock higher. Congrats on the great move!